Introduction
Gene therapy has been proposed as a strategy for the treatment of a variety of genetic and viral diseases. Genetic alteration of the peripheral T lymphocytes has been shown to be of potential therapeutic relevance in inherited diseases, leukemias, and acquired immune deficiency syndrome (AIDS). 1, 2 The central goal of many gene therapy strategies is the efficient and stable delivery of genes. Many advantages are associated with the use of well characterized retroviral vectors for this purpose. However, one of the major limitations associated with using retroviral vectors in gene therapy is their low transducing efficiency. Accordingly, several approaches have been developed to increase retroviral transduction efficiency. Methods include optimization of infection conditions, increasing virus titer, and improving the specificity of the virus for its target cells. In fact, the use of nontargeted retroviral vectors in gene therapy is often considered inadequate since binding to nontarget cells would result in possible side-effects in undesired transduced cells. The use of in vitro transfer protocols, where cells are cultured and transduced ex vivo, can allow partial bypass of these limitations, but restricts the spectrum of diseases which may be treated. In many cases, systematic treatment can only be achieved through the use of retroviral vectors that will deliver genes to specific cells in vivo and enable efficient expression in these cells.
Targeting retroviral vectors to specific cells can be achieved through inducible transcriptional control or preferably by achieving a specific infection of the desired cells by targeted transduction. The latter approach requires modification of the proteins involved in receptor recognition. Retroviruses use a variety of receptors to enter cells; some of these receptors such as the ecotropic and amphotropic murine leukemia virus (MuLV) receptors and many of the immunodeficiency-causing lentivirus receptors have been identified. [3] [4] [5] [6] [7] [8] However, targeted delivery of a murine-based retroviral vector to a specific subpopulation of human cells has yet to be truly achieved. Initial attempts to change viral tropism were done through the use of pseudotyped viruses; [9] [10] [11] MuLV is able to incorporate vesicular stomatitis virus G glycoprotein (VSV-G), influenza virus hemagglutinin (HA), or heterologous retroviral glycoproteins, although this expands viral host range rather than restrict cell tropism. Even though several groups have generated chimeric Envligand fusion proteins designed to bind on to transferrin receptor, galactose receptor or the high density lipoprotein receptor, none of these fusion proteins were successfully incorporated into infectious viral particles. 11 The only reported success has been obtained using heregulinEnv fusion proteins binding to the Erb3/4-receptor, thus enabling specific MuLV infection of human breast cancer cell lines. 12 An alternative approach using receptor-single chain antibodies (scFv) fused to Env proteins has given rise to several difficulties; results obtained with low density lipoprotein scFv-Env chimeric proteins are still promising, although virus titers remain poor. 11, 13 Most obstacles found in these strategies arise in the Env postbinding or membrane fusion steps, giving rise to abortive infection. 11 Therefore, whenever possible, it will be preferable to use authentic viral envelope glycoproteins exhibiting specificity towards the desired targeted cells.
Targeted transduction of CD4 ϩ lymphocytes is critical for HIV gene therapy approaches. Although the establishment of HIV-based vectors for such a strategy has been considered, it is more likely that grafting specific components of HIV on to other retroviruses would generate safer vectors. Although HIV's ability to infect nondividing cells is a great advantage over classical retroviral vectors, HIV's specific, targeted tropism for CD4
+ cells must also be considered. 1, 14, 15 Recently, chimeric HIV Env glycoproteins encompassing the cytoplasmic domain of the VSV G-glycoprotein were shown specifically to target VSV infection to CD4 expressing human epithelial HeLa cells. 16 The incorporation of foreign glycoproteins in enveloped viruses, or pseudotyping, is a well known phenomenon. Reported HIV pseudotypes include HIV particles harboring MuLV Env, human T cell leukemia virus (HTLV) Env, VSV-G and herpes simplex virus (HSV) Env. [17] [18] [19] [20] [21] [22] [23] However, the inability of the HIV glycoproteins to be incorporated into MuLV viral particles has kept these envelope glycoproteins from being of potential use in gene therapy. The presence of a 150-amino acid long intracytoplasmic tail in the HIV gp41 transmembrane glycoprotein is believed to be the cause of such restricted incorporation of HIV Env; steric incumbrance and structure incompatibility between the long gp41 cytoplasmic domain and non-HIV matrix or capsid proteins would explain the specific incorporation. 24 This was further confirmed when HIV Gag matrix protein mutations were shown to disrupt the incorporation of HIV Env. [25] [26] [27] Although the incorporation of HIV Env into the viral particle needs a specific interaction with the HIV matrix protein, other retroviral Env glycoproteins seem to bypass this step. 28, 29 This correlates well with the much shorter cytoplasmic domains of most retroviral Env glycoproteins.
We now confirm and extend recent observations by Mammano et al 30 and Schnierle et al, 31 showing that truncation of the cytoplasmic portion of the Env glycoprotein enables its incorporation into heterologous MuLV virions. Furthermore, truncated envelope glycoproteins were efficiently incorporated into HIV virions harboring matrix protein mutations known to affect glycoprotein incorporation. MuLVs harboring the truncated HIV glycoproteins retain normal biological activity and specifically infect HeLa CD4 expressing cells and activated CD4
ϩ peripheral blood lymphocytes (PBLs), as determined by transduction of a lacZ reporter gene. Altogether, these results demonstrate the feasibility of using this approach to specifically transduce genes into the CD4 expressing cell subpopulation for gene therapy purposes.
Results
Incorporation of full-length and truncated HIV Env glycoproteins into viral particles In order to investigate the incorporation of envelope glycoproteins, wild-type HIV Env expression vectors were cotransfected into 293T cells with either HIV Envnegative proviral DNA (HIVGag) or a MuLV GagPolencoding plasmid (MuLVGag, described in Figure 1 ). After a 36 h delay following transfection, cells were subjected to metabolic radiolabeling with 35 S methionine, as described in Materials and methods. Viral proteins were then immunoprecipitated with HIV-positive patient and goat anti-MuLV Gag antisera and analyzed by SDS-PAGE. Cells transfected with the HIV Env-negative DNA or MuLV GagPol encoding plasmid alone expressed, respectively, the HIV or MuLV major Gag viral capsid proteins, p24 (HIV) or p30 (MuLV) (Figure 2a, lanes 2 and  3) . These proteins were also detected in the virus particles recovered by ultracentrifugation of cell supernatants followed by immunoprecipitation (Figure 2b, lanes 2 and 3) . When cells were cotransfected with the HIV Env expression vector and those encoding either HIV or MuLV Gag, the HIV glycoprotein gp120 could also be detected in both cell lysates (Figure 2a, lanes 4 and 5) . However, incorporation of the HIV Env was restricted to the HIV viral particles (Figure 2b , compare lanes 4 and 5).
If the length of the HIV Env cytoplasmic domain is responsible for such a specific virion incorporation, full truncation of this domain should abrogate this restriction to virion incorporation and should confer to truncated HIV glycoproteins broad pseudotyping abilities, comparable with those of MuLV or other retroviral glycoproteins. To look into such a possibility, cells were again cotransfected with either the proviral HIV Env-negative plasmid or the MuLV GagPol encoding plasmid, and an expression vector encoding a HIV Env glycoprotein deleted of its carboxy-terminal 144-amino acids (HIVEnv⌬713-856, Figure 1b) . Analysis of radioimmunoprecipitated proteins shows that the HIV Env truncated glycoproteins are correctly processed (Figure 2a , lanes 6 and 7) and incorporated into both HIV and MuLV virions (Figure 2b, lanes 6 and 7) . This establishes that the specific incorporation of the HIV Env glycoproteins into the HIV viral particle, and the exclusion of such glycoproteins from other enveloped viruses thereof, is dependent on the presence of the HIV Env long cytoplasmic domain.
To investigate further the role of the HIV Env cytoplasmic domain in its specific incorporation into the HIV viral particle, an HIV Env-negative proviral DNA harboring a small deletion (amino acids 16-18) in the HIV matrix protein was generated (Figure 1b ). This small deletion has been previously identified as abrogating HIV Env virion incorporation. 25, 32 This proviral DNA construct was cotransfected into cells with either the wild-type HIV Env, truncated HIV Env or MuLV Env glycoprotein expression vectors. Although the major capsid proteins (MuLV p30 and HIV p24) and all the different Env glycoproteins (MuLV gp70 and HIV gp120) could be detected in the cell lysates ( Figure 
Figure 1 Schematic representation of plasmids and expression vectors. (a) MuLV-based plasmids. All plasmids contain an SV40 origin of replication, and transcription is driven by a CMV promoter. 36 pHIT111 is peculiar in that the CMV promoter is fused to the R region of the 5′ MuLV LTR. This plasmid also harbors a neo resistance gene under transcriptional control of the SV40 promoter and 3′ MuLV LTR sequences. (b) HIV-based plasmids. Transcription is driven by the HIV LTR, and therefore needs the presence of Tat for efficient expression of the reporter gene, and the SVCMVTat plasmid is thus used to supply Tat in experiments involving the HIV Env encoding plasmids and MuLVGag. All plasmids contain an SV40 origin of replication. The Env-negative proviral HIV plasmids HXBH10Env(-)KpnIfs 37 harbor an ATG to ACG point mutation at the initiation codon of Env and a KpnI frameshift at HIV-HxBc2 nucleotide position 5934. A stop codon at position 7902 is inserted in the HIV truncated-Env glycoprotein expression vector HIVEnv⌬713-856, resulting in the deletion of the cytoplasmic domain of the glycoproteins. 30 A small deletion in the p17-matrix encoding portion of the gag gene in HXBH10Env-(KpnIfs) ⌬16-18 abrogates wild-type Env viral incorporation.
interaction with the HIV p17-matrix protein.
The deletion of such a cytoplasmic domain eliminates any need for such a specific interaction, thereby rendering possible incorporation into MuLV virions.
Infectivity of pseudotyped MuLV virions
Incorporation of the truncated HIV Env glycoproteins into the MuLV viral particle being established, it was then necessary to determine if the pseudotyped MuLV viruses had incorporated fully functional envelope glycoproteins giving rise to infectious viruses. If such is the case, the viruses should specifically infect CD4 ϩ cells. Either the HIV Env-negative proviral DNA, the HIV p17-matrix mutant Env-negative proviral DNA or the MuLVGag expression vector were thus cotransfected in COS cells with the HIV Env, truncated HIV Env, or MuLV Env encoding vectors, as described in Materials and methods. Cotransfections using MuLVGag vector also included a plasmid harboring a lacZ gene and RNA viral encapsidation sequences (Figure 1a) . Such encapsidation sequences being absent on MuLVEnv or MuLVGag, lacZ RNA is thus exclusively incorporated into MuLV virions using this approach. Conversely, the HIV p17-mutant or wild-type Env-negative full-length RNAs are encapsidated into their respective viral particles in all experiments involving HIV. Cell supernatants were harvested 48 h after transfection, and relative amounts of recovered virus were estimated by reverse transcriptase
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Figure 2 Expression and assembly of MuLV and HIV viral proteins. (a) Cells were cotransfected with the relevant Gag and Env encoding plasmids. Viral proteins were immunoprecipitated with an HIV-positive human serum combined with goat anti-MuLV Gag and anti-MuLV Env antisera, and resolved on an 11% SDS-PAGE gel. (b) Incorporation of glycoproteins in released HIV or MuLV virions. Labeled viral pellets were lysed in RIPA buffer, and immunoprecipitated as in (a) and viral proteins resolved on an 11% SDS-PAGE gel. Labeled proteins were then revealed by autoradiography. Position of molecular weight markers is shown and viral proteins are indicated by arrows.
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+ cells R Lodge et al (RT) assay. Equivalent amounts of virus produced from each cotransfection were used to infect either HeLa, HeLaCD4 or HeLaCD4LTR␤-gal cells. Following infection, cells were fixed and stained as described in Materials and methods.
As expected, in HeLa cells, only MuLV-based viruses harboring the amphotropic MuLV envelope glycoprotein were able to transduce the lacZ gene (Figure 3) . Since HeLa cells lack the CD4 receptor, all viruses harboring HIV glycoproteins did not infect the cells. Moreover, the HIV-based viruses used in this study do not possess intrinsic lacZ transduction ability, and therefore do not provide further information when used on these cells (Figure 3b) .
In HeLaCD4 cells, similar transduction efficiencies were obtained with MuLV-based viruses having incorporated either the amphotropic MuLV Env or the truncated HIV Env glycoproteins (Figure 3a) . Use of all other viruses resulted in background ␤-galactosidase activity ( Figure 3) . Again, no detection of HIV-based viruses was expected using these cells. The susceptibility of HeLaCD4 cells to the MuLV viruses harboring the truncated HIV Env demonstrates the functional capacity of such an envelope glycoprotein to mediate specific infection of CD4 ϩ cells and confirms the lack of incorporation of wild-type HIV Env in MuLV. Furthermore, the infectious potential of viruses harboring amphotropic Env or truncated HIV Env appears to be similar.
Finally, virus infection was tested on HeLaCD4LTR␤-gal cells. These cells harbor in their genome a lacZ gene under the transcriptional control of the HIV LTR promoter. Following HIV infection, and production of the Tat transactivating protein, they will thus express ␤-galactosidase activity due to Tat-mediated LTR transactivation. 33 In these cells, MuLV-mediated lacZ transduction was obtained when using the HIV truncated-Env or amphotropic MuLV Env glycoproteins, as in the HeLaCD4 cells (Figure 3a) . Furthermore, HIVs having incorporated wild-type or truncated Env glycoproteins also efficiently gave rise to ␤-galactosidase activity in the cells, through Tat transactivation of endogenous lacZ (Figure 3b) . However, mutant HIVs harboring the mutation in p17 known to prevent incorporation of HIV Env glycoproteins, remained uninfectious in the case of the wild-type HIV glycoproteins only (Figure 3c 
Reporter lacZ gene transduction in activated PBLs
Since the truncated HIV Env glycoproteins enable MuLVs to infect CD4 ϩ HeLa cells specifically, it should be possible to take advantage of such a mechanism to infect primary human cells expressing the CD4 receptor. MuLVs harboring either HIV truncated Env or amphotropic MuLV Env glycoproteins were added to PHA-acti-
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Following a delay to allow sufficient ␤-galactosidase expression, cells were fixed and stained for ␤-galactosidase expression. However, sensitivity of this assay was poor. PCR Southern analysis was therefore used to detect transduced lacZ DNA in infected cells. PCR was used to generate a fragment of 480 bp of the lacZ gene, and the nature of the reaction product was confirmed by Southern blot using a specific 
Specificity of infection in PBLs
Although the specific infection of the CD4 ϩ cell population was suggested by the inhibitory effect of antibodies against gp120, CD4/CD8 cell sorting was further performed in order to identify the activated PBL populations targeted by the pseudotyped MuLVs. Activated PBLs were infected as described previously and sorted into separate CD4 expressing and CD8 expressing PBL subpopulations. A typical distribution of a sorted infected cell population is shown in Figure 4b . Subpopulations of CD4 ϩ or CD8 ϩ cells were then lysed and PCR Southern blot analysis performed to determine which subpopulation supported lacZ transduction. Both CD4 ϩ and CD8 2-7) . Moreover, control cellular GADPH single-copy DNA could be detected at DNA levels similar to that of transduced lacZ in cells infected with the amphotropic virus. Since controls for lacZ and GADPH PCRs reveal similar efficiency in serial dilutions of plasmids harboring the respective genes (results not shown), this suggests that transduction efficiency with the amphotropic virus is close to 100%. Therefore, despite the fact that infection was performed under conditions optimized for MuLV Env, truncated HIV Env viruses transduced lacZ efficiently, approaching 20-25% of the CD4 ϩ cells.
Discussion
In the present study, it was demonstrated that an HIV Env in which the 144 carboxy-terminal amino acids of the cytoplasmic domain have been deleted can still be incorporated into wild-type HIV particles. This contrasts with the situation observed with smaller deletions showing altered incorporation into the virion. 34 These observations can be reconciled, however, since the HIV Env with a complete truncation of its intracytoplasmic domain is also incorporated into HIV viruses harboring known matrix mutations that normally interfere with HIV Env incorporation. 27, 28 Truncation of the cytoplasmic HIV Env domain apparently alleviates any need for specific HIV Gag interaction, effectively converting the incorporation mechanisms to that of shorter cytoplasmicdomain glycoproteins. Accordingly, the truncated glycoprotein was incorporated into MuLV viral particles, in contrast to full-length envelope. Similar observations were also reported by other groups. 30, 31 Nevertheless, in order for the truncated glycoprotein to be useful for retroviral vectors, it must retain the general features of the wild-type glycoprotein, namely, correct processing, CD4 ϩ interaction and membrane fusion, all prerequisites to the release of the nucleocapsid into the cytoplasm. In fact, it proved to be, that in CD4 expressing HeLa cells, the infectious potential of the pseudotyped MuLV viruses was comparable to that of MuLV viruses harboring amphotropic MuLV Env, or HIV viruses possessing either full-length or truncated forms of HIV Env, as previously reported. 30 Moreover, pseudotyped viruses exhibited similar infectivity without the additional presence of full-length MuLV or HIV Env, as was shown necessary in the case of chimeric ligand-Env glycoproteins. 35 Finally, specific, targeted infection of the CD4 ϩ PBL subpopulation was obtained using the MuLV-based vector pseudotyped with the truncated HIV Env. Interestingly, despite the fact that infection was performed under conditions optimized for MuLV Env, truncated HIV Env viruses transduced PBLs with only slightly inferior efficiency to that of amphotropic MuLV viruses. These modified viral vectors are thus able to recognize efficiently and specifically infect CD4 ϩ cells in a mixed cell population.
There could be numerous advantages in using such a vector in gene therapy for AIDS. The true tropism of HIV, including possible CD4-independent cell tropism, should be retained by such pseudotyped viruses. Furthermore, tropism to CD4 ϩ macrophages or lymphocytes could be achieved by pseudotyping MuLV with truncated macrophage-tropic or T-tropic HIV Env glycoproteins. Access to CD4
ϩ nondividing cells (such as dendritic cells and macrophages) could eventually be obtained by grafting other functional elements of the HIV virus, such as the HIV matrix or Vpr proteins, on to MuLV viral vectors coated with such HIV truncated Env glycoproteins. This strategy could retain desired functions of the HIV virus while alleviating the potential of HIV replication through recombination events, or even synthesis of most HIV proteins, in gene therapy treatments. These CD4 ϩ cell-targeted MuLV vectors strategies are to be developed with
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Figure 4 (a) LacZ transduction of PBLs as determined by PCR amplification of lacZ and Southern analysis. MuLV viruses harboring various glycoproteins were produced in COS cells and used to infect PBLs as described in Materials and methods, with or without concomitant addition of antigp120. Cells were then lysed and genomic DNA extracted. PCR was performed on aliquots of extracted DNA, followed by Southern blotting and hybridization with a lacZ specific probe. (b) Representative distribution of CD4 and CD8 populations of infected cells as determined by FACS analysis. Aliquots (2-3 × 10 5 ) of infected cells were treated with a mix of anti-CD8 fluorescein isothiocyanate and anti-CD4 phycoerythrin-conjugated antibodies and sorted with a FACSTAR cell sorter. (c) Southern analysis of transduced cells following sorting. Infected cells were sorted as CD4 ϩ or CD8 ϩ cells, and transduction of lacZ was determined by PCR amplification and Southern analysis as in (a). Amplification of a GADPH gene fragment was performed in parallel on each DNA sample and the results are presented at the bottom of (a) and (c).
the goal of delivering inhibitors of HIV replication in specific cells. Such viral targets could include either early or late steps in the viral replicative cycle. Therapeutic strategies include transduction of genes inhibiting proviral integration or gene expression, or activating suicide genes in HIV-infected cells. The use of gene therapy in AIDS could therefore focus on poorly accessible HIV susceptible cells, which harbor latent viruses, that remain the origin of viral resistance encountered within the current antiretroviral therapies. Finally, the system developed in the present report is of great relevance for the study of gene expression in specific CD4 ϩ cell populations.
Materials and methods
Proviral constructs and expression plasmids Plasmids pHIT60 and pHIT456 respectively encode the GagPol protein of MuLV and the amphotropic Env glycoprotein of MuLV. The pHIT111 plasmid harbors a lacZ gene under the transcriptional control of a modified CMV promoter that is fused to the R-U3 regions of the 5′ MuLV LTR and ⌿-encapsidation sequences. All the pHIT plasmids were obtained from AJ Kingsman (Oxford University, Oxford, UK). 36 Plasmid pSVIIIEnv713 was created by cloning the KpnI-BamHI (corresponding to nucleotide positions 5893 and 8017 of HIV HXBc2 proviral DNA, respectively; +1 = site of initiation of transcription) segment of HXBH10⌬CT, 30 a proviral DNA containing a stop codon in env (corresponding to a TCA to TAA substitution at HIV-HxBc2 nucleotide position 7902), and encoding an Env truncated of its cytoplasmic domain (obtained from Heinrich G Gö ttlinger, DFCI, Boston, MA, USA) in pSVIIIEnv, the vector used for expression of Env under the control of the HIV LTR promoter. The Env-negative proviral construct harboring a mutation in the matrix protein HXBH10Env-(KpnIfs)⌬16-18 was generated by cloning the SalI-BamHI (HXBH10 nucleotide positions 5372 and 8058, respectively; +1 = site of initiation of transcription) fragment of HXBH10Env-(KpnIfs) into HXBH10⌬16-18; both plasmids have been described elsewhere. 25, 37, 38 Cell lines and antisera The 293T, COS, HeLa, HeLaCD4 39 and HeLaCD4LTR␤-gal 33 cells were maintained in DMEM supplemented with 5% fetal calf serum (FCS) and 1% streptomycin and penicillin. Human antiserum No. 162 against HIV proteins has been described elsewhere. 37 The goat antiserum against MuLV Gag (76S000127 and 79S000804) was obtained from Quality Biotech (Biological Carcinogenesis Branch, NCI, Camden, NJ, USA); antiserum raised against MuLV Env (80S00019) was also obtained from Quality Biotech.
Transfection, metabolic radiolabeling and radioimmunoprecipitation DNA transfection in 293T cells (10 6 ) was performed using liposomes, as previously described. 37 Briefly, 10 g of the GagPol encoding plasmids (pHIT60, HXBH10Env-(KpnIfs) or HXBH10Env-(KpnIfs)⌬16-18) were cotransfected with 15 g of one of the following Env encoding plasmid constructs: pHIT456, pSVIIIEnv or pSVIIIEnv713. When pHIT60 was cotransfected with the HIV Env or truncated HIV Env plasmid expression vectors, 5 g of a HIV transactivating protein (Tat) encoding plasmid (SVCMVTat) was added to the DNA mix before transfection, since transcription of both Env genes is driven by the HIV LTR, and their efficient expression is thus dependent on the presence of Tat. Following a 36 h transient expression period, cells were labeled with 150 Ci/ml of 35 S methionine (Tran 35 S-label; ICN Biomedicals, Irvine, CA, USA) for 8 h in methionine freemedium. Supernatants were harvested and ultracentrifuged (100 000 g for 1 h in a Beckman Ti50.4 rotor; Beckman Instruments, Mississauga, Ontario, Canada) to generate a crude viral pellet; cells and viral pellets were then resuspended in RIPA lysis buffer (10 mm Tris-HCl (pH 7.4), 1mm EDTA, 100 mm NaCl, 1% Triton X-100, 0.1% SDS, 0.25% sodium deoxycholate, 0.2% phenylmethylsulfonyl fluoride (PMSF)). Viral proteins present in lysed cells or viral pellets were immunoprecipitated with a mix consisting of HIV-positive human, goat anti-MuLV Gag and goat anti-MuLV Env antisera (all used at 1:5000 dilutions) and loaded on to an 11% SDS-PAGE gel as described previously. 37 Labeled proteins were then revealed by autoradiography.
Infectivity assay using ␤-galactosidase activity The infectivity assay used to determine if viruses harboring the different Env glycoproteins retained infectious capacity was similar to the one described by Kimpton and Emerman, 33 with several modifications, in order to comply with the MuLV lacZ transduction strategy elaborated by Soneoka et al. 36 Briefly, COS cells were lipofected with various combinations of GagPol encoding DNA and Env expression vectors as described in the previous section. Furthermore, 15 g of the pHIT111 lacZ vector was added to every transfection when pHIT60 was present, in order to obtain lacZ transduction through MuLV viruses. At 40 h after transfection, viruses were harvested in 2 ml of DMEM supplemented with 8% FCS and filtered on 0.45 mm pore diameter filters (Millipore, Bedford, MA, USA) to remove cellular debris. A reversetranscriptase assay was performed on aliquots of the filtered supernatants 40, 41 to determine virus yield. Equivalent amounts of the HIV (100 000 c.p.m.) or MuLV (150 000 c.p.m.) viruses were used to infect either HeLa, HeLaCD4 or HeLaCD4LTR␤-gal cells, seeded the previous day in 24-well plates at 3 × 10 4 cells per well. Polybrene (10 g/ml) was added to the infected cells and diluted 8 h into the infection with fresh DMEM supplemented with 8% FCS and antibiotics. Finally, cells were washed, fixed and stained as previously described 33 40 h after the start of infection and the number of blue cells determined using light microscopy.
Culture, isolation and infection of PBLs
Peripheral blood mononuclear cells (PBMCs) were obtained from volunteers by Ficoll-Paque centrifugation as recommended by the manufacturer (Pharmacia, Baie d'Urfé, Québec, Canada) and washed thoroughly to remove platelets. PBLs were enriched from the PBMCs by two-step adherence to remove contaminating macrophages. Cells were cultured in the presence of phytohemagglutinin (PHA, 5 g/ml) for 72 h to obtain activated lymphocytes. Following activation, cells were washed several times to remove the lectin and were maintained in RPMI supplemented with glutamine and 10% FCS, penicillin-streptomycin (100 U/ml), gentamycin (10 g/ml) and 20 U/ml interleukin-2 (rIL2; Boehringer Mannheim, Laval, Quebec, Canada) at 37°C in a 5% CO 2 incubator. Infection of PBLs was performed in conditions similar to those described by Bunnell et al. 42 Briefly, 1 × 10 6 PBLs were seeded in six-well plates, at 2 ml per well, in phosphate-free RPMI supplemented with 10% FCS and rIL2 for 8 h, since phosphate depletion has been shown to enhance MuLV receptor expression in susceptible cells. Subsequent to the phosphate depletion step, cells were exposed to viruses (at a MOI of 0.1 as determined by the number of blue cells obtained with HeLaCD4LTR␤-gal cells) and centrifuged at low speed and 32°C for 60 min in a Beckmann GS-6R centrifuge (Beckman Instruments). Following centrifugation, cells were incubated for 12 h at 32°C, washed and maintained in RPMI supplemented with 10% FCS, rIL2 and the antibiotics as above. A second series of infected cells was treated with sheep anti-gp120 at a dilution of 1:250 throughout the infection procedure in order to determine the specificity of the viruses for targeting the CD4 ϩ cell population.
Analysis of infected PBLs by PCR and Southern blot
A lacZ PCR Southern blot strategy was used to detect transduced lacZ DNA in PBLs. Briefly, cells were lysed by repeated freezing and thawing, cell nuclei pelleted and treated with proteinase K (0.1 mg/ml)-1% SDS in Trisbuffered saline for 4 h at 50°C. DNA was extracted by two steps of phenol-chloroform and ethanol precipitation. A fifth of this crude extract was used to detect lacZ gene transduction by PCR amplification. Amplification was carried out using Taq DNA polymerase (Perkin Elmer, Norwalk, CT, USA) and required 30 cycles of 1 min at 94°C; 2 min at 50°C and 3 min at 72°C. The primers used to amplify lacZ were 5′-CTTCTATAGA CACGCAAACAC-3′ (sense) and 5′-CCCGTCGGA TTCTCCGTGGG-3′ (antisense). Detection of the lacZ sequence was performed by Southern blotting and hybridization with a probe corresponding to the homologous lacZ region and generated by nick-translation using ␣ 32 P-dATP (3000 Ci/mmol; ICN Radiochemicals, Irvine, CA, USA). The glyceraldehyde-3 phosphate dehydrogenase (GADPH) primers that were used as internal PCR amplification controls were 5-GCTGATGCCCCCATG TTCGT-3 (sense oligonucleotide) and 5-CAAAGG TGGAGGAGTGGGTGT-3 (antisense oligonucleotide). The GADPH amplified product was detected using a probe covering the entire GADPH sequence 43 and generated by nick-translation.
FACS analysis of the transduced cells was performed with Cyto-Stat/Coulter Clone T8-FITC anti-CD8 fluorescein isothiocyanate or T4-RD1 anti-CD4 phycoerythrinconjugated antibodies (Coulter Corporation, Miami, FL, USA). Following extensive washing, approximately 1-2 × 10 5 CD4 ϩ or CD8 ϩ cells were sorted using a FAC-STAR cell sorter (Becton Dickinson, Mountain View, CA, USA). Sorted cells were lysed and analyzed for lacZ transduction by PCR and Southern blot analysis as previously described. Quantification of signals on autoradiograms was performed with a Molecular Dynamics Personal Densitometer (Sunnyvale, CA, USA) using ImageQuant software.
